Vasoactive Intestinal Peptide (VIP): Physiological Functions, Testing Methods, and Research Applications
DISCLAIMER
The peptide discussed in this article, Vasoactive Intestinal Peptide (VIP), is intended exclusively for research purposes by licensed researchers. It is NOT approved for human or animal in vivo testing or consumption. All information provided is for educational purposes only. This article reviews published scientific research but does not advocate for or promote the use of VIP outside properly regulated research settings.
Introduction to VIP
Vasoactive intestinal peptide (VIP), originally identified in 1970 as a vasodilator, is a 28-amino acid peptide hormone that has since been discovered to have multiple physiological and pathological effects. Its influence extends to development, growth, and the control of neuronal, epithelial, and endocrine cell functions. These functions in turn regulate ion secretion, nutrient absorption, gut motility, glycemic control, carcinogenesis, immune responses, and circadian rhythms[1].
The sequence of VIP has been remarkably well conserved during evolution from protochordates to mammals, suggesting an important biological function. With a molecular weight of 3,326 Da, VIP belongs to the glucagon-growth hormone-releasing factor secretion superfamily[4]. It is primarily found in the intestines, pancreas, and central nervous system, but is also present in the respiratory and urogenital tracts, as well as exocrine, thyroid, and adrenal glands[6].
Research into VIP has expanded significantly in recent decades, revealing its complex roles in maintaining physiological homeostasis and its potential as a therapeutic target for various conditions. This article provides a comprehensive overview of VIP’s physiological functions, methods for testing VIP levels, and current research applications.
Physiological Functions of VIP
Vasodilatory Actions
As its name suggests, VIP is a potent vasodilator. Close intra-arterial infusion of VIP increases blood flow in the gastric, small intestinal, and colonic mucosa in experimental animal models. According to research, “VIP acts as a potent vasodilator. Close intra-arterial infusion of VIP increases blood flow in the gastric, small intestinal, and colonic mucosa in cats and rats”[1].
The vasodilatory effects of VIP are mediated through specific mechanisms: “Vasodilatory effects of VIP are mediated via VPAC1 activation on endothelial cells, followed by release of NO, and via VPAC2 activation on vascular smooth muscle cells in the porcine basilar arteries”[1]. This dual pathway of action allows VIP to effectively modulate vascular tone in different tissues.
Steinhorn et al. demonstrated that “VIP elicits potent endothelium-dependent and -independent vasodilation in the peripheral microcirculation”[7]. This vasodilatory function makes VIP an important regulator of local blood flow, particularly in the gastrointestinal system and other highly vascularized tissues.
Gastrointestinal Functions
VIP plays multiple critical roles in gastrointestinal function. It regulates ion transport, mucus secretion, tight junction protein expression, and cell proliferation, mainly through activation of VPAC1 receptors. Research indicates that “VIP effects on epithelial functions, including ion transport, mucus secretion, tight junction protein expression, and cell proliferation, are mainly mediated via VPAC1 activation”[1].
One of the key functions of VIP in the gastrointestinal tract is the regulation of epithelial paracellular permeability through its effects on tight junction proteins. Studies have shown that “VIPergic pathways increase the expression of the tight junction protein zonula occludens-1 (ZO-1) in human polarized colonic epithelial monolayers co-cultured with human submucosa containing the submucosal plexus, associated with reduced epithelial paracellular permeability”[1]. Furthermore, “VIP also ameliorates bacterial infection-induced intestinal barrier disruption by preventing the translocation of tight junction proteins ZO-1, occludin, and claudin-3 in a Citrobacter rodentium-induced colitis model”[1].
VIP also influences gastric acid secretion through indirect mechanisms: “VIP inhibits gastric acid secretion via VPAC1 activation on D cells and SST release”[1]. This demonstrates the complex regulatory role of VIP in digestive processes.
Immune System Regulation
VIP exhibits significant immunomodulatory properties, functioning primarily as an anti-inflammatory mediator. According to research, “Vasoactive intestinal peptide (VIP) is a mediator that modulates all the stages comprised between the arrival of pathogens and Th cell differentiation in RA through its known anti-inflammatory and immunomodulatory actions”[5].
In rheumatoid arthritis (RA), VIP has been shown to modulate “the pathogenic activity of diverse cell subpopulations involved in RA as lymphocytes, fibroblast-like synoviocytes (FLS), or macrophages”[5]. Additionally, “VIP decreases the expression of pattern recognition receptor (PRR) such as toll-like receptors (TLRs) in FLS from RA patients”[5], further supporting its anti-inflammatory role.
VIP also plays a role in regulating mucosal immunity by modulating immunoglobulin synthesis. Wu et al. demonstrated that “Vasoactive intestinal polypeptide (VIP) modulates the immunoglobulin (Ig) synthesis in the peripheral blood of humans and in various lymphoid organs of other species”[8]. Specifically, their research showed that “the addition of VIP was associated with a significant increase in the production of IgA, whereas IgG levels were significantly reduced”[8]. This selective effect on different antibody classes illustrates the nuanced role of VIP in immune regulation.
Neurological Functions and Circadian Rhythm
In the central nervous system, VIP serves as a neurotransmitter and plays a crucial role in regulating circadian rhythms through its actions in the hypothalamic suprachiasmatic nuclei (SCN). Research by Hamnett et al. revealed that “SCN cells expressing vasoactive intestinal polypeptide (VIP) or its cognate receptor, VPAC2, are neurochemically and electrophysiologically distinct, but together they control de novo rhythmicity, setting ensemble period and phase with circuit-level spatiotemporal complexity”[9].
This research identified the VIP/VPAC2 cellular axis as “a neurochemically and topologically specific pacemaker hub that determines the emergent properties of the SCN timekeeper”[9]. This finding highlights the central role of VIP in maintaining proper circadian rhythms, which in turn affect numerous physiological processes.
Wu et al. demonstrated that “the application of VIP produced an increase in electrical activity in SCN slices that lasted several hours after treatment”[14]. They noted that “this is a novel mechanism by which this peptide can produce long-term changes in central nervous system physiology”[14]. The persistence of this effect suggests that VIP can induce lasting neuroplastic changes in the central nervous system.
VIP Receptors and Signaling
VIP exerts its effects by binding to specific G protein-coupled receptors, primarily VPAC1 and VPAC2. These receptors are differentially expressed in various tissues and cell types, mediating the diverse functions of VIP.
VPAC1 is “constitutively expressed on T cells and macrophages but less on dendritic cells, mast cells, and neutrophils”[1]. In the gastrointestinal tract, “VPAC1 localization in the epithelial cells is thought to be on the basolateral membranes, since serosally applied VIP increases electrogenic anion secretion in the small and large intestine”[1]. However, research has also shown VPAC1 “immunolocalized to the apical membranes of mouse and human colonic epithelial cells”[1].
VPAC2, on the other hand, is expressed on vascular smooth muscle cells and plays a role in VIP-induced vasodilation[1]. In the central nervous system, particularly in the SCN, the VIP/VPAC2 signaling pathway is crucial for maintaining circadian rhythms[9].
Binding of VIP to its receptors activates adenylyl cyclase, leading to increased intracellular cAMP levels and activation of downstream signaling pathways. Research has shown that “inhibitors of both the Epac family of cAMP binding proteins and cAMP-dependent protein kinase (PKA) blocked the induction [of increased electrical activity] by VIP” in SCN neurons[14]. This indicates that both Epac and PKA signaling pathways are involved in mediating VIP’s effects on neuronal activity.
Pathological Conditions Related to VIP
VIP Deficiency and Autoimmune Disorders
VIP deficiency has been associated with various pathological conditions, particularly autoimmune disorders. In rheumatoid arthritis, patients with low VIP serum levels have been found to demonstrate a worse clinical disease course[16].
Genetic studies have identified polymorphisms in the VIP gene that correlate with serum VIP levels and clinical parameters in early arthritis patients. Research found that “patients with rs688136 CC genotype showed higher VIP levels” in both discovery and validation populations[16]. Furthermore, functional studies revealed “a miRNA-mediated regulatory mechanism explaining the higher VIP gene expression in homozygous patients”[16].
VIP deficiency has also been linked to alterations in gut microbiota. Forster et al. found that “VIP deficiency would alter gut microbial ecology”[10]. Their research observed “significant changes in bacterial composition, biodiversity, and weight loss from VIP−/− mice compared to VIP+/+ and VIP+/− littermates, irrespective of sex”[10]. These changes were consistent with gut microbial structure changes reported for certain inflammatory and autoimmune disorders, suggesting a potential mechanistic link between VIP deficiency, altered gut microbiota, and autoimmune conditions.
VIP-Secreting Tumors (VIPomas)
In contrast to VIP deficiency, excessive VIP production can occur in VIP-secreting tumors, known as VIPomas. These rare tumors, most of which (90%) are located in the pancreas, cause a syndrome characterized by watery diarrhea, hypokalemia, and achlorhydria[2][11].
VIPomas produce and release VIP into the blood, leading to elevated VIP levels that can be detected through specific blood tests. “People with VIP-secreting tumors usually have values 3 to 10 times above the normal range”[2]. These tumors represent a rare but important pathological condition associated with VIP dysregulation.
Primary Pulmonary Hypertension
Interestingly, VIP deficiency has been implicated in the pathogenesis of primary pulmonary hypertension (PPH), a fatal disease causing progressive right heart failure. Researchers found “a deficiency of the peptide in serum and lung tissue of patients with primary pulmonary hypertension, as evidenced by radioimmunoassay and immunohistochemistry”[4].
The relevance of this finding is supported by “an upregulation of corresponding receptor sites as shown by Northern blot analysis, Western blot analysis, and immunological techniques”[4]. This compensatory upregulation of VIP receptors suggests that the body is attempting to maximize the effect of the limited available VIP, further highlighting the importance of VIP in maintaining pulmonary vascular function.
Testing Methods for VIP
Blood Tests for VIP Levels
The primary method for measuring VIP levels in clinical and research settings is through blood tests. The Vasoactive Intestinal Peptide (VIP) test measures the amount of VIP in the blood, typically using enzyme-linked immunosorbent assay (ELISA) techniques.
For proper specimen collection, specific protocols must be followed. According to Mayo Clinic Laboratories, the test involves collecting blood in a “lavender top (EDTA) tube, followed by centrifugation and aliquoting plasma into a plastic vial that must be frozen immediately”[11]. The specimen must be frozen to preserve the integrity of the VIP molecules.
Patients preparing for VIP testing “should not eat or drink anything for 4 hours before the test”[2]. This fasting requirement helps ensure accurate results by minimizing factors that might influence VIP levels.
Normal VIP values are typically “less than 75 pg/mL (22.2 pmol/L)”[2]. In patients with VIPomas, levels are usually “3 to 10 times above the normal range”[2]. It’s important to note that “moderately elevated levels can be caused by other diseases of the gut, including irritation of the gut lining and decreased blood flow in the gut”[2], highlighting the need for clinical correlation when interpreting test results.
Validation of In Vitro Assays
In research settings, proper validation of assays used to measure VIP or study its effects is crucial. The USDA’s Center for Veterinary Biologics has established guidelines for the validation of in vitro potency assays, which could be applied to VIP-related testing[3].
These guidelines emphasize that “all assays, regardless of format or function, must be relevant, reliable, reproducible, and scientifically sound”[3]. They note that “the formal process for evaluating these characteristics is commonly known as validation”[3].
The validation process “begins when the assay is proposed and its relationship to efficacy in the target species is first investigated. Validation continues through the development of the assay as it is first optimized and various aspects of its precision and accuracy are characterized”[3]. This rigorous approach ensures that results from VIP-related assays are reliable and meaningful.
Therapeutic Potential of VIP
Anti-Inflammatory Applications
VIP’s anti-inflammatory properties make it a promising candidate for the treatment of various inflammatory and autoimmune disorders. As previously noted, VIP “modulates all the stages comprising the arrival of pathogens and Th cell differentiation in RA through its known anti-inflammatory and immunomodulatory actions”[5].
Research has shown that VIP can decrease the expression of pattern recognition receptors like toll-like receptors in fibroblast-like synoviocytes from RA patients, potentially reducing the inflammatory response[5]. These findings suggest that VIP or VIP-like molecules could potentially be developed as therapeutic agents for autoimmune conditions.
Cardiovascular Applications
VIP’s vasodilatory effects make it potentially useful for cardiovascular conditions, particularly those involving pulmonary hypertension. A groundbreaking study found that VIP treatment “decreased the mean pulmonary artery pressure in our eight study patients, increased cardiac output, and mixed venous oxygen saturation”[4].
The researchers concluded that their “data provide enough proof for further investigation of vasoactive intestinal peptide and its role in primary pulmonary hypertension”[4]. This suggests that VIP could potentially be developed as a treatment for this otherwise fatal condition.
Gastrointestinal Applications
Given VIP’s extensive roles in gastrointestinal function, there is interest in its potential applications for gastrointestinal disorders. Research has shown that VIP can “ameliorate bacterial infection-induced intestinal barrier disruption by preventing the translocation of tight junction proteins”[1].
VIP’s ability to maintain the integrity of the intestinal epithelial barrier and regulate ion secretion suggests potential therapeutic applications for conditions involving barrier dysfunction, such as inflammatory bowel disease.
Current Research and Future Directions
Liposomal VIP Delivery
An intriguing area of research involves the delivery of VIP using liposomes. Studies have shown that “VIP susceptibility to trypsin- and human plasma-catalyzed cleavage is curtailed when the peptide is inserted on the surface of liposomes”[7].
This approach has demonstrated promising results in experimental models. For instance, research found that “suffusion of VIP on SSL [sterically stabilized liposomes], but not of empty SSL, restores the vasorelaxant effects of VIP in the presence of anti-VIP antibody”[7]. This suggests that liposomal delivery could enhance the stability and efficacy of VIP in potential therapeutic applications.
The researchers concluded that “liposomal VIP is less susceptible to degradation by catalytic VIP autoantibodies compared with aqueous VIP because of decreased binding affinity of liposomal VIP to autoantibodies”[7]. This could potentially overcome one of the key challenges in developing VIP-based therapies.
VIP and Microbiota
The relationship between VIP and gut microbiota represents another frontier in VIP research. Studies have shown that VIP deficiency is associated with “significant changes in bacterial composition, biodiversity, and weight loss” in animal models[10].
These findings suggest that VIP plays “an important role in maintaining microbiota balance, biodiversity, and GIT function”[10]. This could have implications for conditions involving dysbiosis, such as inflammatory bowel disease, and might lead to novel therapeutic approaches targeting the VIP-microbiota axis.
Genetic Studies and Personalized Medicine
Recent genetic studies have identified polymorphisms in the VIP gene that correlate with serum VIP levels and clinical outcomes in conditions like rheumatoid arthritis[16]. This opens up possibilities for personalized medicine approaches based on an individual’s VIP-related genetic profile.
For instance, researchers found that “patients with an rs688136 CC genotype and no minor alleles of the other polymorphisms required less treatment” for early arthritis[16]. This suggests that genetic testing could potentially help predict treatment responses and guide therapeutic decisions in the future.
Conclusion
Vasoactive intestinal peptide (VIP) is a multifunctional neuropeptide with diverse physiological roles across multiple organ systems. Its actions in vasodilation, gastrointestinal function, immune regulation, and circadian rhythm control highlight its biological significance and therapeutic potential.
Testing methods for VIP, particularly blood tests measuring serum levels, provide valuable tools for both clinical diagnosis and research purposes. These methods continue to evolve, with innovative assays being developed to address specific research questions.
The therapeutic potential of VIP is considerable, with possible applications in inflammatory and autoimmune disorders, cardiovascular conditions, gastrointestinal diseases, and neurological disorders. Current research focusing on delivery methods, genetic factors, and microbial interactions promises to expand our understanding of VIP and its therapeutic applications.
As research on VIP continues to advance, it may lead to novel therapeutic approaches for a range of conditions, potentially offering new hope for patients with otherwise difficult-to-treat diseases. However, it is important to emphasize that such applications remain in the research phase, and any clinical use of VIP or VIP-based therapies should occur only within properly regulated clinical trials.
References
Forster, C. M., Wahlström, A., Mitra, S., Arora, J., Näsström, E., Arif, S., … & Larsson, E. (2019). Vasoactive intestinal peptide deficiency is associated with altered gut microbiota communities in mouse models via modulation of antimicrobial peptides. Frontiers in Microbiology, 10, 2689. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2019.02689/full
Ganesan, R., & Murtaugh, R. J. (2024). Vasoactive intestinal peptide test. UCSF Health. https://www.ucsfhealth.org/medical-tests/vasoactive-intestinal-peptide-test
Hamnett, R., Chesham, J. E., Maywood, E. S., Hastings, M. H., & Bechtold, D. A. (2020). The VIP-VPAC2 neuropeptidergic axis is a cellular pacemaking hub of the suprachiasmatic nucleus circadian circuit. Nature Communications, 11(1), 3394. https://www.nature.com/articles/s41467-020-17110-x
Iwasaki, M., Akiba, Y., & Kaunitz, J. D. (2019). Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. F1000Research, 8, F1000 Faculty Rev-1629. https://pmc.ncbi.nlm.nih.gov/articles/PMC6743256/
Mayo Clinic Laboratories. (2019). VIP – Overview: Vasoactive intestinal polypeptide, plasma. https://www.mayocliniclabs.com/test-catalog/overview/8150
Petkov, V., Mosgoeller, W., Ziesche, R., Raderer, M., Stiebellehner, L., Vonbank, K., … & Block, L. H. (2003). Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. The Journal of Clinical Investigation, 111(9), 1339-1346. https://pmc.ncbi.nlm.nih.gov/articles/PMC154449/
Shanlikian, G. (2023). Vasoactive intestinal peptide – Uses, dosage and side effects. Genemedics. https://www.genemedics.com/vasoactive-intestinal-peptide
Steinhorn, B., Sorrentino, A., Badlam, J. B., Chiles, P. G., Datar, S. A., Risbano, M. G., … & Leopold, J. A. (2018). Vasodilation elicited by liposomal VIP is unimpeded by anti-VIP antibody in the in situ hamster cheek pouch. Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 275(1), R56-R60. https://journals.physiology.org/doi/full/10.1152/ajpregu.1998.275.1.R56
Torrento, C., Martínez, C., Juarranz, Y., Rodríguez-Henche, N., Calvo, J. R., Gutiérrez-Cañas, I., … & Gomariz, R. P. (2018). Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis. Scientific Reports, 8(1), 2035. https://www.nature.com/articles/s41598-018-20400-6
USDA Animal and Plant Health Inspection Service. (2015). Guidelines for validation of in vitro potency assays. Veterinary Services Memorandum No. 800.112. https://www.aphis.usda.gov/animal_health/vet_biologics/publications/memo_800_112.pdf
Wu, L., Lau, B., Walker, J., Guo, Y., Wu, J., & Duerksen, D. R. (2010). Vasoactive intestinal polypeptide modulates the in vitro immunoglobulin A production by intestinal lamina propria lymphocytes. Journal of Clinical Immunology, 30(Suppl 1), S19-S25. https://pubmed.ncbi.nlm.nih.gov/8119526/
Wu, Y., Cao, C., Wu, Y., Zhang, M., & La Cour, B. (2013). Vasoactive intestinal peptide produces long-lasting changes in neural activity in the suprachiasmatic nucleus. Journal of Neurophysiology, 110(5), 1097-1106. https://journals.physiology.org/doi/full/10.1152/jn.00114.2013
Sources
[1] Recent advances in vasoactive intestinal peptide physiology and … https://pmc.ncbi.nlm.nih.gov/articles/PMC6743256/
[2] Vasoactive intestinal peptide test – UCSF Health https://www.ucsfhealth.org/medical-tests/vasoactive-intestinal-peptide-test
[3] [PDF] Veterinary Services Memorandum No. 800.112 – usda aphis https://www.aphis.usda.gov/animal_health/vet_biologics/publications/memo_800_112.pdf
[4] Vasoactive intestinal peptide as a new drug for treatment of primary … https://pmc.ncbi.nlm.nih.gov/articles/PMC154449/
[5] The Anti-Inflammatory Mediator, Vasoactive Intestinal Peptide … https://pmc.ncbi.nlm.nih.gov/articles/PMC6092975/
[6] Vasoactive Intestinal Peptide – Uses, Dosage and Side Effects https://www.genemedics.com/vasoactive-intestinal-peptide
[7] Vasodilation elicited by liposomal VIP is unimpeded by anti-VIP … https://journals.physiology.org/doi/full/10.1152/ajpregu.1998.275.1.R56
[8] Vasoactive intestinal polypeptide modulates the in vitro … – PubMed https://pubmed.ncbi.nlm.nih.gov/8119526/
[9] The VIP-VPAC2 neuropeptidergic axis is a cellular pacemaking hub … https://www.nature.com/articles/s41467-020-17110-x
[10] Vasoactive Intestinal Peptide Deficiency Is Associated With Altered … https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2019.02689/full
[11] VIP – Overview: Vasoactive Intestinal Polypeptide, Plasma https://www.mayocliniclabs.com/test-catalog/overview/8150
[12] VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 … https://journals.asm.org/doi/10.1128/mbio.00560-21
[13] CJC 1295 Guide: Uses, Benefits, Dosage, Side Effects, and More https://www.genemedics.com/cjc-1295
[14] Vasoactive intestinal peptide produces long-lasting changes in … https://journals.physiology.org/doi/full/10.1152/jn.00114.2013
[15] In vitro alteration of receptors for vasoactive intestinal peptide … https://pmc.ncbi.nlm.nih.gov/articles/PMC2187477/
[16] Vasoactive intestinal peptide gene polymorphisms, associated with … https://www.nature.com/articles/s41598-018-20400-6
[17] Therapeutic potential of vasoactive intestinal peptide and its … https://pmc.ncbi.nlm.nih.gov/articles/PMC9531956/
[18] Vasoactive intestinal polypeptide plasma levels associated … – Nature https://www.nature.com/articles/s41598-020-80873-2
[19] Vasoactive Intestinal Peptide Potentiates Sexual Behavior: Inhibition … https://academic.oup.com/endo/article-abstract/125/6/2945/2532648
[20] Vasoactive Intestinal Polypeptide Secreting Tumor – VIPoma https://arupconsult.com/content/vasoactive-intestinal-polypeptide-secreting-tumor
[21] A Guide for In Vitro and In Vivo Assays in Early Drug Discovery https://www.promega.com/resources/pubhub/tpub_191-the-assay-guidance-manual/
[22] 7432 – Gene ResultVIP vasoactive intestinal peptide [ (human)] – NCBI https://www.ncbi.nlm.nih.gov/gene/7432
[23] Vasoactive intestinal peptide axis is dysfunctional in patients with … https://www.nature.com/articles/s41598-020-70138-3
[24] Effect of Vasoactive Intestinal Polypeptide on Development of … https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2782759
[25] [PDF] Test Definition: VIP – Mayo Clinic Laboratories https://www.mayocliniclabs.com/test-catalog/download-setup?format=pdf&unit_code=8150
[26] Assay Guidance Manual – NCBI Bookshelf https://www.ncbi.nlm.nih.gov/books/NBK53196/
[27] Research advances of vasoactive intestinal peptide in the … https://pmc.ncbi.nlm.nih.gov/articles/PMC7789055/
[28] Targeting vasoactive intestinal peptide-mediated signaling … – Nature https://www.nature.com/articles/s41467-022-34242-4
[29] MK 677 Ibutamoren Guide 2023: Benefits, Results, Side Effects https://www.genemedics.com/mk-677
[30] Myoelectric effects of vasoactive intestinal peptide on rabbit small … https://journals.physiology.org/doi/10.1152/ajpgi.1983.244.1.G46
[31] In vitro and in vivo treatment of colon cancer by VIP antagonists https://pubmed.ncbi.nlm.nih.gov/12409224/
[32] Peptides for Wound Healing – Genemedics Health Institute https://www.genemedics.com/peptides-for-wound-healing
[33] VIP is involved in peripheral CRF-induced stimulation of propulsive … https://journals.physiology.org/doi/full/10.1152/ajpgi.00308.2017
[34] Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 … https://pubmed.ncbi.nlm.nih.gov/9108448/
[35] VIP: A very important protein in arthritis | Nature Medicine https://www.nature.com/articles/nm0501_537
[36] Myoelectric effects of vasoactive intestinal peptide on rabbit small … https://journals.physiology.org/doi/pdf/10.1152/ajpgi.1983.244.1.G46
[37] Effect of vasoactive intestinal polypeptide (VIP) on the in vitro and in … https://pubmed.ncbi.nlm.nih.gov/7084506/
[38] Activation of Th lymphocytes alters pattern expression and cellular … https://www.nature.com/articles/s41598-019-43717-2
[39] Vasoactive intestinal peptide stimulates mucus secretion, but nitric … https://journals.physiology.org/doi/full/10.1152/japplphysiol.01264.2005